MétaCan
Menu
← Back to cohort
Record W4416607719 · doi:10.1038/s41598-025-28810-z

Expression of carcinoma ecotypes in the tumor microenvironment predicts response to neoadjuvant therapy in early-stage breast cancer

2025· article· en· W4416607719 on OpenAlexafffund
Karama Asleh, Gillian Bethune, Paola Marcato

Bibliographic record

VenueScientific Reports · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsBeatrice Hunter Cancer Research InstituteNova Scotia Health AuthorityDalhousie University
FundersCanadian Institutes of Health ResearchDalhousie University
KeywordsBreast cancerImmunotherapyNeoadjuvant therapyChemotherapyTranscriptomeTumor microenvironmentBreast carcinoma

Abstract

fetched live from OpenAlex

Immunotherapy is associated with modest pathologic complete response (pCR) rates in early-stage breast cancer, and a subset of patients still achieves a pCR after neoadjuvant chemotherapy (NAC) only. Identifying biomarkers in the complex tumor ecosystem which define the subsets of patients who achieve pCR benefit on immunotherapy versus not is of a critical need. Transcriptomic data for patients enrolled in the two neoadjuvant immunotherapy arms of 'pembrolizumab' (n = 69) and 'durvalumab' (n = 71), and the chemotherapy arm 'control' (n = 210) of the I-SPY2 breast cancer clinical trial were included. Using a machine learning algorithm for tumor ecosystem-based classification, we deconvoluted transcriptomic data into the established 10 multicellular organization systems known as 'Ecotypes'. We found that the most pro-inflammatory carcinoma ecotype (CE)9 predicts pCR in the 'pembrolizumab' arm (OR = 2.07; 95% CI 1.35-3.8; adjusted P value = 0.01), in the 'control' arm (OR = 1.89; 95% CI 1.36-2.63; adjusted P value = 0.002), and in the 'durvalumab' arm (OR = 1.66; 95%CI 1.18-2.34; adjusted P value = 0.03). In contrast, the basal-enriched ecotype CE2 was the most significant predictor of pCR in the 'durvalumab' arm, which included the addition of olaparib (OR = 3.22; 95%CI 2.25-4.60; adjusted P value < 0.0001), but not in NAC (OR = 1.18; 95%CI 0.81-1.72; adjusted P value = 0.94). Our findings suggest that CE9 could identify early-stage breast cancer patients who achieve a pCR after neoadjuvant therapy and may have a good prognosis. Whether CE9 patients could still be considered for immunotherapy or be candidates for de-escalation strategies in the neoadjuvant setting requires further investigation in future studies with link to survival outcomes. In contrast, CE2 tumors would benefit from the combination of immunotherapy with olaparib. Integrating tumor ecosystem-based patient classification could guide effective clinical management in early-stage breast cancer.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.001
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.002

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.001
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.011
GPT teacher head0.265
Teacher spread0.254 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes2
Has abstractyes

Explore more

Same venueScientific Reports→Same topicCancer Immunotherapy and Biomarkers→French-language works237,207→